Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective

Neurotherapeutics

Volumn 11, Issue 1, 2014, Pages 111-116

  Payami, Haydeh ^a   Factor, Stewart A ^b  

^a WADSWORTH CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug discovery; Parkinson's disease; Pharmacogenomics; Prevention; Treatment

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CAFFEINE; CATECHOL METHYLTRANSFERASE; DJ 1 PROTEIN; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; ISTRADEFYLLINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NEUROTROPHIC FACTOR; NICOTINE; PRELADENANT; TOLCAPONE;

CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; DNA POLYMORPHISM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESPONSE; GENETIC MARKER; GENOTYPE; HUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; DRUG DISCOVERY; HUMANS; PARKINSON DISEASE; PHARMACOGENETICS;

EID: 84893108288     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0237-y     Document Type: Review

References (57)

1. Factor SA. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 2008;5(2): 164-80.
2. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975;83: 456-63.
3. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. NEJM. 2004;351(24): 2498-508. doi: 10. 1056/NEJMoa033447.
4. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3): 448-58.
5. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000;57: 263-7.
6. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009;24: 647-54. doi: 10. 1002/mds. 22432.
7. Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics 2013;14: 1085-97. doi: 10. 2217/pgs. 13. 81.
8. Maliepaard M, Nofziger C, Papaluca M, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013;12(2): 103-15.
9. Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3: 90.
10. Chan A, Pirmohamed M, Comabella M. Pharmacogenomics in neurology: Current state and future steps. Ann Neurol 2011;70: 684-97.
11. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet. 2011;20(3): 528-40.
12. Schroder A, Klein K, Winter S, et al. Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J. 2013;13(1): 12-20.
13. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends in Pharmacological Sciences 2004;25: 193-200.
14. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 2013;339: 1563-6.
15. Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis. Int J Cardiol. 2013;168(4): 4234-4. doi: 10. 1016/j. ijcard. 2013. 07. 151.
16. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010;8: 331-73.
17. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013;28: 210-5.
18. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13: 1285-306.
19. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. NEJM. 2008;358: 568-79.
20. Arbouw ME, Guchelaar HJ, Egberts TC. Novel insights in pharmacogenetics of drug response in Parkinson's disease. Pharmacogenomics 2010;11: 127-9.
21. Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Int J Clin Pract. 2011;65: 1289-94.
22. Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal 2013;11: 34.
23. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010;68: 201-6.
24. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol. 2013;9(8): 445-54.
25. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41: 1303-7.
26. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010;42: 781-5.
27. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet. 2011;19: 655-61.
28. Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011;7: e1002141.
29. Lill CM, Roehr JT, McQueen MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 2012;8(3): e1002548.
30. Pankratz N, Beecham GW, DeStefano AL, et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71: 370-84.
31. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol. 2012;30: 1117-24.
32. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41: 1105-9.
33. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262): 399-401.
34. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41(10): 1100-4.
35. Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27: 5972-8.
36. Group SC, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. NEJM 2008;359(8): 789-99.
37. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Péer I, Floratos A et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41: 816-9.
38. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42: 711-4.
39. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8: 186-95.
40. Hamza TH, Chen H, Hill-Burns EM, et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet. 2011;7(8): e1002237.
41. Hill-Burns EM, Singh N, Ganguly P, et al. A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. Pharmacogenomics J 2012; doi: 10. 1038/tpj. 2012. 38.
42. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem. 2006;98: 1866-75.
43. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001;21: RC143.
44. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52: 276-84.
45. Powers K, Kay D, Factor S, et al. Combined effects of smoking, coffee and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23: 88-95.
46. Dorus S, Vallender EJ, Evans PD, et al. Accelerated evolution of nervous system genes in the origin of Homo sapiens. Cell 2004;119: 1027-40.
47. Caudle WM, Zhang J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 2009;220: 230-3.
48. Higley MJ, Sabatini BL. Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 2010;13: 958-66.
49. Turner TJ. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J Neurosci 2004;24: 11328-36.
50. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476: 214-9.
51. Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79: 651-8.
52. Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacol 2012;37: 213-46.
53. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43: 507-13.
54. Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003;184: 285-94.
55. Hodgson RA, Bedard PJ, Varty GB, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 2010;225: 384-90.
56. Dungo R, Deeks ED. Istradefylline: first global approval. Drugs. 2012;73: 875-82.
57. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10: 221-9.